Janssen-Cilag Pty Ltd

Tecvayli (teclistamab) has been provisionally approved for the treatment of relapsed or refractory multiple myeloma in adult patients.

AusPAR for Rybrevant (amivantamab) for treatment of patients with NSCLC that has an EGFR exon 20 insertion mutation.

For the treatment of adult patients with relapsing forms of multiple sclerosis

AusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis

Australian Public Assessment Report for Ad26.COV2.S

Australian Public Assessment Report for Esketamine hydrochloride

Australian Public Assessment Report for Guselkumab

Australian Public Assessment for Apalutamide

Australian Public Assessment Report for Guselkumab

Australian Public Assessment Report for Paliperidone palmitate